venBio
View Older Stories View More Recent Stories
-
Immunomedics Files Federal Lawsuit Against venBio for Continuing Material Violations of the Federal Securities Laws
-
Form SC 13D/A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
Immunomedics Sends Letter to Stockholders Highlighting Value Creating Global Licensing Agreement, Underscoring Fulfillment of Promise to Stockholders
-
Immunomedics Comments on Baseless venBio Lawsuit
-
Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
Form 13F-HR venBio Select Advisor For: Dec 31
-
venBio Takes Steps to Protect Immunomedics (IMMU) Stockholders Following Its Partnership with Seattle Genetics (SGEN)
-
venBio Takes Steps to Protect Rights of Immunomedics Stockholders
-
Form SC 13G/A Nabriva Therapeutics AG Filed by: venBio Global Strategic Fund II L.P.
-
Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
venBio Comments on Immunomedics Partnership Announcement
-
Form SC 13G AGENUS INC Filed by: venBio Select Advisor LLC
-
Form SC 13G/A Lion Biotechnologies, Filed by: venBio Select Advisor LLC
-
Form SC 13G/A Mirati Therapeutics, Filed by: venBio Select Advisor LLC
-
Form SC 13G ALIMERA SCIENCES INC Filed by: venBio Select Advisor LLC
-
Form SC 13G Oncobiologics, Inc. Filed by: venBio Select Advisor LLC
-
Immunomedics Announces Second Quarter Fiscal 2017 Results and Clinical Program Developments
-
Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
Immunomedics Strongly Encourages Stockholders to Reject the venBio Nominees — With Four New Independent Directors and a Robust Value-Maximization Process, Stockholders Should Not Risk Giving venBio
-
Glass Lewis Endorses Full Slate of venBio Nominees at Immunomedics
-
Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
ISS Endorses Full Slate of venBio Nominees at Immunomedics
-
Immunomedics Mails Letter to Stockholders Highlighting Strength of New Board and Deep Engagement in Robust, Value-Creating Strategic and CMC Processes
-
OrbiMed Comments on Immunomedics Proxy Contest
-
Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
Immunomedics Sets the Record Straight in New Presentation
-
venBio Calls on Immunomedics Stockholders to Support Meaningful Change
-
Immunomedics Issues Statement to Stockholders and Files Investor Presentation
-
Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
venBio Releases Presentation Detailing Urgent Case for Change at Immunomedics
-
Immunomedics Mails Letter to Stockholders
-
Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
venBio Sends Letter to Immunomedics Stockholders
-
Immunomedics to Mail Letter to Stockholders Highlighting Unprecedented Progress Toward Enhanced Value Creation
-
Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
venBio Sends Letter to Immunomedics Stockholders
-
Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
venBio Responds to Immunomedics Announcement
-
Immunomedics Announces Reconstituted Board of Directors and Leadership Succession Plan
-
Form DEFC14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
Impel NeuroPharma Announces $36M Funding to Advance Novel Drug Delivery Platform for Central Nervous System Disorders
-
Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
Form PRRN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
venBio Responds to Immunomedics’ Postponement of Annual Meeting
-
Immunomedics (IMMU) Announces Postponement of Annual Meeting of Stockholders
-
Immunomedics Postpones 2016 Annual Meeting of Stockholders
-
Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
venBio Comments on its Recent Nomination of Four Highly-Qualified Candidates for Board of Immunomedics, Inc.

